Levokabastin

Levokabastin

IUPAC ime
(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
Klinički podaci
Kategorija trudnoće	AU: B3 US: C (Mogući rizik)
Način primene	Oftalmično, intranazalno[1]
Pravni status
Pravni status	℞ (Prescription only)
Farmakokinetički podaci
Poluvreme eliminacije	3
Identifikatori
CAS broj	79516-68-0 Y
ATC kod	R01AC02 (WHO) S01GX02
PubChem	CID 54385
IUPHAR/BPS	1586
DrugBank	APRD01069
ChemSpider	16736421 Y
UNII	H68BP06S81 Y
KEGG	D08117 Y
ChEMBL	CHEMBL1201312 Y
Hemijski podaci
Formula	C26H29FN2O2
Molarna masa	420.519 g/mol
SMILES Fc1ccc(cc1)[C@]2(CC[C@@H](CC2)N3CC[C@@]([C@H](C)C3)(c4ccccc4)C(O)=O)C#N
InChI InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1 Y Key:ZCGOMHNNNFPNMX-KYTRFIICSA-N Y
НY (šta je ovo?)

Levokabastin je selektivni antagonist H₁ receptora druge generacije koji je razvila kompanija Jansen Farmaceutikal 1979. On se koristi za lečenje alergijskog konjunktivitisa.^[2]

Pored antihistaminskog dejstva, levokabastin takođe deluje kao potentan i selektivan antagonist neurotenzinskog receptora NTS₂, i bio je prvi lek koji je korišten za karakterisanje raznih neurotenzinskih podtipova.^{[3][4][5][6][7][8][9]}

1. ^ „RxMed: Pharmaceutical Information - LIVOSTIN NASAL SPRAY”. Приступљено 13. 11. 2005. 
2. ^ Pipkorn U, Bende M, Hedner J, Hedner T., A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy. 1985 Oct;40(7):491-6.
3. ^ Schotte A, Leysen JE, Laduron PM (1986). „Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain”. Naunyn-Schmiedeberg's Archives of Pharmacology. 333 (4): 400—5. PMID 3022160. doi:10.1007/BF00500016. 
4. ^ Kitabgi P, Rostène W, Dussaillant M, Schotte A, Laduron PM, Vincent JP (1987). „Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution”. European Journal of Pharmacology. 140 (3): 285—93. PMID 2888670. doi:10.1016/0014-2999(87)90285-8. 
5. ^ Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D (1996). „Molecular cloning of a levocabastine-sensitive neurotensin binding site”. FEBS Letters. 386 (2-3): 91—4. PMID 8647296. doi:10.1016/0014-5793(96)00397-3. 
6. ^ Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP (1996). „Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain”. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 16 (18): 5613—20. PMID 8795617. 
7. ^ Sarret P, Esdaile MJ, Perron A, Martinez J, Stroh T, Beaudet A (2005). „Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors”. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 25 (36): 8188—96. PMID 16148226. doi:10.1523/JNEUROSCI.0810-05.2005. 
8. ^ Bredeloux P, Costentin J, Dubuc I (2006). „Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice”. Behavioural Brain Research. 175 (2): 399—407. PMID 17074405. doi:10.1016/j.bbr.2006.09.016. 
9. ^ Yamauchi R, Wada E, Kamichi S, Yamada D, Maeno H, Delawary M, Nakazawa T, Yamamoto T, Wada K (2007). „Neurotensin type 2 receptor is involved in fear memory in mice”. Journal of Neurochemistry. 102 (5): 1669—76. PMID 17697051. doi:10.1111/j.1471-4159.2007.04805.x.